Analysts Set Repligen Co. (NASDAQ:RGEN) Price Target at $185.20

Shares of Repligen Co. (NASDAQ:RGEN) have earned an average recommendation of “Moderate Buy” from the thirteen research firms that are presently covering the stock, Marketbeat Ratings reports. Five analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $185.20.

A number of equities analysts have issued reports on the company. StockNews.com upgraded Repligen from a “sell” rating to a “hold” rating in a report on Friday, January 3rd. Royal Bank of Canada reissued an “outperform” rating and set a $205.00 price target on shares of Repligen in a research report on Thursday, September 26th. Canaccord Genuity Group started coverage on shares of Repligen in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price objective on the stock. Wolfe Research assumed coverage on shares of Repligen in a report on Thursday, November 14th. They set a “peer perform” rating for the company. Finally, Canaccord Genuity Group assumed coverage on Repligen in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target on the stock.

Institutional Trading of Repligen

Institutional investors have recently added to or reduced their stakes in the business. UMB Bank n.a. raised its stake in shares of Repligen by 138.3% in the third quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 130 shares during the last quarter. Blue Trust Inc. raised its position in Repligen by 113.4% in the 3rd quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock worth $36,000 after buying an additional 127 shares during the last quarter. Resources Management Corp CT ADV bought a new position in Repligen during the 3rd quarter valued at about $37,000. Quarry LP boosted its holdings in shares of Repligen by 796.7% during the 3rd quarter. Quarry LP now owns 269 shares of the biotechnology company’s stock valued at $40,000 after acquiring an additional 239 shares during the last quarter. Finally, nVerses Capital LLC bought a new stake in shares of Repligen in the third quarter worth approximately $45,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Repligen Price Performance

Shares of NASDAQ RGEN opened at $156.55 on Friday. Repligen has a 1 year low of $113.50 and a 1 year high of $211.13. The stock has a market capitalization of $8.77 billion, a P/E ratio of -423.10, a P/E/G ratio of 4.64 and a beta of 0.97. The company’s 50-day moving average is $147.36 and its 200 day moving average is $143.99. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76.

Repligen (NASDAQ:RGEN) last posted its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, topping analysts’ consensus estimates of $0.34 by $0.09. The firm had revenue of $154.87 million for the quarter, compared to the consensus estimate of $153.34 million. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The business’s revenue for the quarter was up 9.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.23 EPS. On average, sell-side analysts expect that Repligen will post 1.54 earnings per share for the current year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.